Differential network analysis applied to preoperative breast cancer chemotherapy response

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Warsow, Gregor ^a,b,c   Struckmann, Stephan ^a   Kerkhoff, Claus ^d   Reimer, Toralf ^a   Engel, Nadja ^a   Fuellen, Georg ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^d UNIVERSITY OF OSNABRÜCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; TRANSCRIPTION FACTOR GATA 3;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; COMPUTER PREDICTION; COMPUTER PROGRAM; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE INTERACTION; GENE TARGETING; HUMAN; HUMAN CELL; INFORMATION PROCESSING; INFORMATION RETRIEVAL; LIVER CELL CARCINOMA; MELK GENE; MYBL2 GENE; ONCOGENE; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; VALIDITY;

BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; PROTEIN INTERACTION MAPPING; PROTEIN-SERINE-THREONINE KINASES; SOFTWARE; TRANS-ACTIVATORS;

EID: 84891945257     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081784     Document Type: Article

References (48)

1. Ideker T, Ozier O, Schwikowski B, Siegel AF (2002) Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics 18 Suppl 1:S233-S240. (Pubitemid 41185658)
2. Breitling R, Amtmann A, Herzyk P (2004) Graph-based iterative group analysis enhances microarray interpretation. BMC Bioinformatics 5:100.
3. Cabusora L, Sutton E, Fulmer A, Forst CV (2005) Differential network expression during drug and stress response. Bioinformatics 21:2898-2905. (Pubitemid 40862290)
4. Nacu S, Critchley-Thorne R, Lee P, Holmes S (2007) Gene expression network analysis and applications to immunology. Bioinformatics 23:850-858. (Pubitemid 47049919)
5. Ulitsky I, Karp RM, Shamir R (2008) Detecting disease-specific dysregulated pathways via analysis of clinical expression profiles. In: Proceedings of the 12th annual international conference on Research in computational molecular biology. Berlin, Heidelberg: Springer-Verlag, RECOMB'08, pp. 347-359. URL http://dl.acm.org/citation.cfm?id=1804315.1804345.
6. Ideker T, Sharan R (2008) Protein networks in disease. Genome Res 18:644-652. (Pubitemid 351482789)
7. Dao P, Wang K, Collins C, Ester M, Lapuk A, et al. (2011) Optimally discriminative subnetwork markers predict response to chemotherapy. Bioinformatics 27:i205-i213.
8. Ideker T, Krogan NJ (2012) Differential network biology. Mol Syst Biol 8:565.
9. Baumbach J, Friedrich T, Koetzing T, Krohmer A, Muller J, et al. (2012) Efficient algorithms for extracting biological key pathways with global constraints. In: Proceedings of the fourteenth international conference on Genetic and evolutionary computation conference. ACM, pp. 169-176. URL http://dl.acm.org/citation.cfm?id=2330188.
10. Chuang HY, Lee E, Liu YT, Lee D, Ideker T (2007) Network-based classification of breast cancer metastasis. Mol Syst Biol 3:140.
11. Gevaert O, De Smet F, Timmerman D, Moreau Y, De Moor B (2006) Predicting the prognosis of breast cancer by integrating clinical and microarray data with bayesian networks. Bioinformatics 22:e184-e190. (Pubitemid 44288285)
12. Staiger C, Cadot S, Kooter R, Dittrich M, Mller T, et al. (2012) A critical evaluation of network and pathway-based classifiers for outcome prediction in breast cancer. PLoS One 7:e34796.
13. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, et al. (2011) The string database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39:D561-D568.
14. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, et al. (2010) Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12:R5.
15. Warsow G, Greber B, Falk S S I, Harder C, Siatkowski M, et al. (2010) Expressence-revealing the essence of differential experimental data in the context of an interaction/regulation net-work. BMC Syst Biol 4:164.
16. Alcaraz N, Friedrich T, Ktzing T, Krohmer A, Mller J, et al. (2012) Efficient key pathway mining: combining networks and omics data. Integr Biol (Camb) 4:756-764.
17. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, et al. (2012) A travel guide to cytoscape plugins. Nat Methods 9:1069-1076.
18. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
19. Engel N, Lisec J, Piechulla B, Nebe B (2012) Metabolic profiling reveals sphingosine-1-phosphate kinase 2 and lyase as key targets of (phyto-) estrogen action in the breast cancer cell line mcf-7 and not in mcf-12a. PLoS One 7:e47833.
20. Liedtke C, Mazouni C, Hess KR, Andr F, Tordai A, et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281.
21. Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, et al. (2007) Positive cross-regulatory loop ties gata-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 67:6477-6483. (Pubitemid 47037533)
22. Chou J, Provot S, Werb Z (2010) Gata3 in development and cancer differentiation: cells gata have it! J Cell Physiol 222:42-49.
23. Abba MC, Nunez MI, Colussi AG, Croce MV, Segal-Eiras A, et al. (2006) Gata3 protein as a muc1 transcriptional regulator in breast cancer cells. Breast Cancer Res 8:R64.
24. Long BH, Fairchild CR (1994) Paclitaxel inhibits progression of mitotic cells to g1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 54:4355-4361. (Pubitemid 24273147)
25. Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, et al. (2009) In vitro and in vivo analysis of b-myb in basal-like breast cancer. Oncogene 28:742-751.
26. Pickard MR, Green AR, Ellis IO, Caldas C, Hedge VL, et al. (2009) Dysregulated expression of fau and melk is associated with poor prognosis in breast cancer. Breast Cancer Res 11:R60.
27. Raschell G, Cesi V, Amendola R, Negroni A, Tanno B, et al. (1999) Expression of b-myb in neuroblastoma tumors is a poor prognostic factor independent from mycn amplification. Cancer Res 59:3365-3368. (Pubitemid 29334493)
28. Hebbard LW, Maurer J, Miller A, Lesperance J, Hassell J, et al. (2010) Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. Cancer Res 70:8863-8873.
29. Joaquin M, Watson RJ (2003) The cell cycle-regulated b-myb transcription factor overcomes cyclindependent kinase inhibitory activity of p57 (kip2) by interacting with its cyclin-binding domain. J Biol Chem 278:44255-44264. (Pubitemid 37377170)
30. Lin D, Fiscella M, O'Connor PM, Jackman J, Chen M, et al. (1994) Constitutive expression of b-myb can bypass p53-induced waf1/cip1-mediated g1 arrest. Proc Natl Acad Sci U S A 91:10079-10083. (Pubitemid 24311952)
31. Sala A, Casella I, Bellon T, Calabretta B, Watson RJ, et al. (1996) B-myb promotes s phase and is a downstream target of the negative regulator p107 in human cells. J Biol Chem 271:9363-9367. (Pubitemid 26139921)
32. Liekens A M L, De Knijf J, Daelemans W, Goethals B, De Rijk P, et al. (2011) Biograph: unsupervised biomedical knowledge discovery via automated hypothesis generation. Genome Biol 12:R57.
33. Davis AP, Murphy CG, Johnson R, Lay JM, Lennon-Hopkins K, et al. (2013) The comparative toxicogenomics database: update 2013. Nucleic Acids Res 41:D1104-D1114.
34. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and uorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244. (Pubitemid 46630780)
35. Nakano I, Paucar AA, Bajpai R, Dougherty JD, Zewail A, et al. (2005) Maternal embryonic leucine zipper kinase (melk) regulates multipotent neural progenitor proliferation. J Cell Biol 170:413-427. (Pubitemid 41126941)
36. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, et al. (1995) Taxol induction of p21waf1 and p53 requires c-raf-1. Cancer Res 55:4623-4626.
37. Brugarolas J, Bronson RT, Jacks T (1998) p21 is a critical cdk2 regulator essential for proliferation control in rb-deficient cells. J Cell Biol 141:503-514. (Pubitemid 28237097)
38. Vantieghem K (2006) Photoproduction of Vitamin D3 and Activation into 1a, 25-dihydroxyvitamin D3 in Human Epidermal Keratinocytes, Dermal Fibroblasts and Other Cells. Number 371 in Acta Biomedica Lovaniensia. Leuven University Press, 117 pp.
39. Verlinden L, Eelen G, Beullens I, Van Camp M, Van Hummelen P, et al. (2005) Characterization of the condensin component cnap1 and protein kinase melk as novel e2f target genes down-regulated by 1, 25-dihydroxyvitamin d3. J Biol Chem 280:37319-37330. (Pubitemid 41642337)
40. Seong HA, Gil M, Kim KT, Kim SJ, Ha H (2002) Phosphorylation of a novel zinc-finger-like protein, zpr9, by murine protein serine/threonine kinase 38 (mpk38). Biochem J 361:597-604. (Pubitemid 34177828)
41. Seong HA, Kim KT, Ha H (2003) Enhancement of b-myb transcriptional activity by zpr9, a novel zinc finger protein. J Biol Chem 278:9655-9662. (Pubitemid 36800462)
42. Calvisi DF, Simile MM, Ladu S, Frau M, Evert M, et al. (2011) Activation of vmyb avian myeloblastosis viral oncogene homolog-like2 (mybl2)-lin9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53. Hepatology 53:1226-1236.
43. Mannefeld M, Klassen E, Gaubatz S (2009) B-myb is required for recovery from the dna damageinduced g2 checkpoint in p53 mutant cells. Cancer Res 69:4073-4080.
44. Tegze B, Szllsi Z, Haltrich I, Pnzvlt Z, Tth Z, et al. (2012) Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS One 7:e30804.
45. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 295:2492-2502. (Pubitemid 43854964)
46. Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel Q G C M, et al. (2006) Molecular subtypes of breast cancer and amplification of topoisomerase ii alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 95:1334-1341. (Pubitemid 44760082)
47. Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, et al. (2010) Age/race differences in her2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer 116:2549-2559.
48. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, et al. (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 103:250-263.